Company news
Replimune Group, Inc. (NASDAQ:REPL) news
Replimune Group, Inc. news releases on 6ix. Latest, Oct 1, 2026: Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
Press releases & updates
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
October 1, 2026
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
September 30, 2026
Replimune to Present at the Cantor Global Healthcare Conference 2026
September 3, 2026
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
August 14, 2026
Replimune Announces Pricing of $150 Million Underwritten Offering
August 10, 2026
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
August 6, 2026
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
July 30, 2026
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
June 29, 2026
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
June 26, 2026
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 31, 2026
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 29, 2026
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
May 29, 2026
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2026
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
February 2, 2026
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
November 6, 2025
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
November 5, 2025
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
October 19, 2025
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
October 18, 2025
Replimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights - REPL
September 22, 2025
Replimune Provides Update Following Type A Meeting with FDA
September 17, 2025
Replimune Announces Type A Meeting Scheduled with FDA
September 1, 2025
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
August 6, 2025
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
July 21, 2025
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2025
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2025
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
May 28, 2025
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
May 21, 2025
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
May 15, 2025
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2025
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 6, 2025
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
February 11, 2025
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
January 20, 2025
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
January 7, 2025
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 22, 2024
Replimune Announces Proposed Public Offering
November 24, 2024
Replimune Announces Pricing of Upsized Public Offering
November 24, 2024
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
November 20, 2024
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
November 11, 2024
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 8, 2024
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 29, 2024
Replimune to Present at Two Upcoming Investor Conferences
September 30, 2024
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
September 14, 2024
Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
September 8, 2024
Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024
August 21, 2024
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
August 12, 2024
Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
August 7, 2024
Replimune Announces $100 Million Private Placement Financing
June 12, 2024
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 6, 2024
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
June 5, 2024